SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Has Average Price Target of $10.00 According to Brokerages

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have earned a consensus rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.00.

Several analysts have recently issued reports on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st.

SOPHiA GENETICS Trading Up 2.1%

NASDAQ:SOPH opened at $7.30 on Tuesday. SOPHiA GENETICS has a 52-week low of $3.75 and a 52-week high of $8.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The stock has a fifty day simple moving average of $7.88 and a 200-day simple moving average of $6.15. The company has a market capitalization of $612.40 million, a PE ratio of -6.35 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities research analysts expect that SOPHiA GENETICS will post -0.77 earnings per share for the current fiscal year.

Insider Activity at SOPHiA GENETICS

In related news, insider Zhenyu Xu sold 17,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the sale, the insider owned 590,887 shares in the company, valued at approximately $4,307,566.23. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $79,982.94. Following the sale, the chief executive officer owned 660,391 shares in the company, valued at approximately $5,368,978.83. This trade represents a 1.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 291,543 shares of company stock valued at $2,181,326. Company insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently bought and sold shares of the stock. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the 2nd quarter valued at $9,809,000. Principal Financial Group Inc. raised its holdings in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the period. Hodges Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at about $2,157,000. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. Finally, 1492 Capital Management LLC grew its holdings in shares of SOPHiA GENETICS by 8.4% during the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after purchasing an additional 17,406 shares during the period. Institutional investors and hedge funds own 31.59% of the company’s stock.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Myriad Genetics and SOPHiA GENETICS are partnering with AstraZeneca to use prostate cancer technology involving genomic-instability scoring. The agreement provides potential commercial and validation benefits for SOPH by connecting its analytics capabilities with Myriad’s testing expertise and AstraZeneca’s oncology development programs. Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
• Positive Sentiment: The collaboration reinforces SOPHiA GENETICS’ positioning in cancer genomics and could increase adoption of its cloud-based SOPHiA DDM platform. However, the reports do not disclose financial terms, revenue guidance or a specific near-term contribution, so the immediate earnings impact remains uncertain. SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
• Neutral Sentiment: Several executives and directors, including the CEO, chairman, CFO and CTO, sold shares at approximately $8.04–$8.13. The sales were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial position. SOPHiA GENETICS insider trading report
• Negative Sentiment: The broad group of insider sales totaled roughly $669,000 and may create some near-term selling pressure or investor caution, despite the transactions appearing administrative rather than discretionary bearish bets.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.